Sjögren’s disease (SjD) is a debilitating autoimmune disorder that has long been overlooked in the pharmaceutical landscape. Affecting millions worldwide, it leads to chronic dryness, joint pain, and systemic complications that can severely impact quality of life. Despite its widespread prevalence, no FDA-approved advanced treatments exist—until now.
Johnson & Johnson has announced a major milestone in the fight against Sjögren’s disease: Nipocalimab, an investigational monoclonal antibody, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This decision follows last year’s Breakthrough Therapy Designation (BTD), making Nipocalimab the first and only therapy to receive such recognition for this condition.
Why This Matters: Addressing a Major Unmet Need
Nipocalimab is part of a new class of therapies that target FcRn, a protein responsible for regulating levels of immunoglobulin G (IgG) antibodies, including autoantibodies—a key driver of autoimmune diseases.
But what exactly are autoantibodies?
In a healthy immune system, antibodies help fight off infections by recognizing and attacking harmful invaders like bacteria and viruses. Autoantibodies, however, are a mistake of the immune system—instead of targeting external threats, they attack the body’s own tissues, leading to chronic inflammation and tissue damage.
In Sjögren’s disease, autoantibodies contribute to the destruction of moisture-producing glands, causing severe dryness, joint pain, fatigue, and systemic complications that can impact multiple organs.
By blocking FcRn, Nipocalimab may lower autoantibody levels without compromising the immune system’s ability to fight infections—offering a more precise and safer approach to treating autoimmune diseases.
The Phase 2 DAHLIAS trial demonstrated remarkable results, with:
> Over 70% improvement in disease activity compared to placebo
> More than 77% reduction in IgG autoantibodies
> Trends of improvement across multiple symptoms
This success has set the stage for the ongoing Phase 3 DAFFODIL study, which is currently enrolling patients and could pave the way for the first-ever FDA-approved advanced therapy for Sjögren’s disease.
A Closer Look at Nipocalimab: How Does It Work?
Nipocalimab is part of a new class of therapies that target FcRn, a protein responsible for regulating levels of immunoglobulin G (IgG) antibodies, including autoantibodies that drive autoimmune diseases.
What’s Next?
This Fast Track designation marks the fourth time the FDA has prioritized Nipocalimab, reinforcing its potential to transform treatment across multiple autoimmune conditions. Beyond Sjögren’s disease, Nipocalimab has also received Fast Track or Orphan Drug designation for conditions like hemolytic disease of the fetus and newborn (HDFN), warm autoimmune hemolytic anemia (wAIHA), and fetal neonatal alloimmune thrombocytopenia (FNAIT).
With an FDA submission on the horizon, the approval of Nipocalimab could redefine the landscape for autoimmune disease treatment—not just for Sjögren’s disease, but for a broader spectrum of conditions driven by autoantibodies.
For patients who have waited far too long for a breakthrough, the future is looking brighter than ever.
Sources:
- Johnson & Johnson Press Release, March 18, 2025
- ClinicalTrials.gov – DAHLIAS Study (NCT04968912)